Home » Stocks » Windtree Therapeutics

Windtree Therapeutics, Inc. (WINT)

Stock Price: $9.20 USD 0.26 (2.91%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $9.01 -0.19 (-2.07%) Aug 7, 7:55 PM

Stock Price Chart

Key Info

Market Cap 126.01M
Revenue (ttm) 158,000
Net Income (ttm) -27.47M
Shares Out 13.70M
EPS (ttm) -2.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $9.20
Previous Close $8.94
Change ($) 0.26
Change (%) 2.91%
Day's Open 8.95
Day's Range 8.88 - 9.25
Day's Volume 51,079
52-Week Range 4.00 - 14.97

More Stats

Market Cap 126.01M
Enterprise Value 114.97M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 13.70M
Float 3.46M
EPS (basic) -2.39
EPS (diluted) -2.35
FCF / Share -1.57
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5,727
Short Ratio 0.14
Short % of Float 0.15%
Beta 0.30
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 797.56
PB Ratio 1.55
Revenue 158,000
Operating Income -24.94M
Net Income -27.47M
Free Cash Flow -21.50M
Net Cash 11.05M
Net Cash / Share 0.81
Gross Margin -7,904.43%
Operating Margin -15,784.18%
Profit Margin -17,387.30%
FCF Margin -13,609.49%
ROA -13.88%
ROE -41.29%
ROIC -9,481.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$12.25*
Low
12.3
Current: $9.20
High
12.3
Target: 12.25
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.201.791.492.040.992.840.390.200.58-
Revenue Growth-88.93%20.4%-27.28%106.89%-65.19%630.67%98.97%-66.49%--
Gross Profit0.201.791.492.040.060.16-0.130.200.58-
Operating Income-24.89-16.20-22.55-38.04-39.83-43.26-44.51-37.82-24.51-25.53
Net Income-27.48-20.53-18.45-39.49-55.17-44.06-45.22-37.32-20.97-19.18
Shares Outstanding10.931.500.340.140.120.100.070.050.030.01
Earnings Per Share-2.51-23.20-72.42-284.52-478.81-470.41-688.79-797.99-781.19-1,385.99
Operating Cash Flow-24.66-15.78-21.05-33.59-33.50-41.17-40.45-32.88-22.70-24.27
Capital Expenditures-0.190.01-0.02-0.25-0.19-0.78-0.61-0.64-0.11-0.10
Free Cash Flow-24.85-15.77-21.07-33.84-33.69-41.95-41.06-33.52-22.80-24.37
Cash & Equivalents22.7325.322.045.8138.9544.9486.6127.2910.5910.61
Total Debt6.317.97-25.0025.0020.3618.500.220.290.44
Net Cash / Debt16.4217.342.04-19.1913.9524.5768.1127.0810.3010.17
Assets1191193.359.7044.3847.5089.3229.9413.3214.54
Liabilities44.0451.2827.2738.5336.1128.3030.8212.2912.068.51
Book Value74.9468.11-23.92-28.838.2719.2058.5017.651.266.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Windtree Therapeutics, Inc.
Country United States
Employees 31
CEO Craig E. Fraser

Stock Information

Ticker Symbol WINT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: WINT
IPO Date August 8, 1995

Description

Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.